Annotation Detail

Information
Associated Genes
EPAS1
Associated Variants
EPAS1 OVEREXPRESSION ( ENST00000263734.5 )
EPAS1 OVEREXPRESSION ( ENST00000263734.5 )
Associated Disease
renal cell carcinoma
Source Database
CIViC Evidence
Description
HIF-2A (EPAS1) staining was conducted on 66 tumors. Of the 66 patients, 25 were classified as responders and 41 were classified as non-responders. There was no significant difference between responders and non-responders with regards to overall response rate to pazopanib (44% vs 33%; P=0.36).
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1673
Gene URL
https://civic.genome.wustl.edu/links/genes/1705
Variant URL
https://civic.genome.wustl.edu/links/variants/435
Rating
3
Evidence Type
Predictive
Disease
Renal Cell Carcinoma
Evidence Direction
Does Not Support
Drug
Pazopanib
Evidence Level
B
Clinical Significance
N/A
Pubmed
23881929
Drugs
Drug NameSensitivitySupported
PazopanibN/Afalse